

I. AMENDMENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-9. (canceled)

Claim 10. (currently amended) A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin or to a biologically active contortrostatin variant so that contortrostatin or said contortrostatin variant binds to the integrin, wherein said contortrostatin variant comprises an amino acid sequence at least 90% identical to amino acid numbers 419 to 483 of SEQ ID NO: 2 as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

Claim 11. (canceled) ~~A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin so that contortrostatin binds to the integrin.~~

Claim 12. (withdrawn) A homodimeric disintegrin comprising an amino acid sequence which is at least 90% percent identical to amino acid numbers 419 to 483 of SEQ ID NO: 2, wherein said contortrostatin amino acid sequence (i) binds to integrin $\alpha v \beta 5$ and (ii) induces $\alpha v \beta 3$ -mediated tyrosine phosphorylation of CAS and FAK in tumor cells.

Claim 13. (withdrawn) The homodimeric disintegrin of claim 12 having an amino acid sequence selected from the group consisting of:

- (a) amino acid numbers 419 to 483 of SEQ ID NO: 2;
- (b) an amino acid sequence at least 95% identical to (a) as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

Claim 14. (withdrawn) A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a homodimeric disintegrin according to claim 12.

Claim 15. (new) The method of claim 10, wherein said integrin is $\alpha v \beta 3$ or $\alpha v \beta 5$.

Claim 16. (new) The method of claim 10, wherein the cells are exposed to contortrostatin.

II. RESPONSE TO RESTRICTION REQUIREMENT

In response to the restriction requirement, Applicants elect Group I, claims 10 and 11 drawn to methods of inhibiting adhesion, with traverse.